Table 2.

Correlation of EPAS1 mutations with clinicopathological features of patients with esophageal squamous cell carcinoma.

Features	Number	Negative	Positive	P-value
Total patients		80	74 (92.5%)	6 (7.5%)
Sex
Male	67 (83.8%)	62 (92.5%)	5 (7.5%)	0.66
Female	13 (16.2%)	12 (92.3%)	1 (7.7%)
Age
≤60	54 (67.5%)	48 (88.9%)	6 (11.1%)	0.02
>60	26 (32.5%)	26 (100%)	0 (0%)
Site
Upper or middle	53 (66.3%)	50 (94.3%)	3 (5.7%)	0.32
Lower	27 (33.7%)	24 (88.9 %)	3 (11.1%)
Size (cm)
≤6	31 (38.7%)	29 (93.5%)	2 (6.5%)	0.57
>6	49 (61.3%)	45 (91.8%)	4 (8.2%)
Differentiation
Well	24 (30.0%)	23 (95.8%)	1 (4.2%)	0.65
Moderate	39 (48.8%)	36 (93.3%)	3 (7.7%)
Poor	17 (21.2%)	15 (88.2%)	2 (11.8%)
T-stages
I & II	6 (7.5%)	5 (83.3%)	1 (16.7%)	0.38
III & IV	74 (92.5%)	69 (93.2%)	5 (6.8%)
Lymph-node metastasis
Presence	60 (75.0%)	54 (90.0%)	6 (10.0%)	0.05
Absence	20 (25.0%)	20 (100%)	0 (0.0%)
Distant metastasis
Yes	5 (6.3%)	4 (80.0%)	1 (20.0%)	0.33
No	75 (93.7%)	70 (93.3%)	5 (6.7%)
Stage
I & II	22 (27.5%)	21 (95.5%)	1 (4.5%)	0.47
III & IV	58 (72.5%)	53 (91.4%)	5 (8.6%)

Bold values indicates p-value of 0.05 or below.